Our news

27.04.2018

NeoPhore and PhoreMost Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme

Grant award funds expanded operations and recognizes innovative drug discovery programme 27th April 2018, Cambridge, UK – NeoPhore Limited, a cancer i…

11.04.2018

NeoPhore Appoints Jeffrey Roix as Chief Executive Officer

NeoPhore Limited, a cancer immuno-oncology company, today announced the appointment of Jeffrey Roix as Chief Executive Officer, with immediate…

08.01.2018

NeoPhore Appoints Pioneering Cancer Researchers and Clinicians to Scientific Advisory Board

Company attracts world-leading researchers who discovered the role of mismatch repair biology in cancer and cancer immunotherapy NeoPhore Limited, a…

29.11.2017

NeoPhore Scientific Founders Publish Breakthrough Immuno-oncology Discoveries in Nature

Collaboration by company and founders will offer further insights into DNA repair and cancer immunity The internationally recognised scientific…

Other news

30.11.2017

Neophore to prod cancer into neoantigen expression by targeting DNA mismatch repair

The founders of the U.K.-listed gene editing technology firm Horizon Discovery plc, Alberto Bardelli and Chris Torrance, have re-emerged in a new…